ArticleAesthetic plastic surgery2026
Comparative Evaluation of Exosomes, Mesenchymal Stem Cells, and Nanofat on Cartilage Graft Viability in a Rat Model.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCartilage grafts are widely used in aesthetic and reconstructive procedures; however, their long-term success depends on the preservation of chondrocyte viability and extracellular matrix integrity following transplantation. Adipose-derived products, including nanofat, mesenchymal stem cells, and stem cell-derived exosomes, have emerged as potential biological adjuncts to enhance graft survival. This study aimed to compare the effects of nanofat, adipose-derived mesenchymal stem cells (ADMSCs), and ADMSC-derived exosomes on the viability of auricular cartilage grafts in a rat model. We hypothesized that exosome treatment would improve extracellular matrix preservation and increase type II collagen expression.
methodsTwenty-four male Wistar rats (6 months old, approximately 400 g) received four auricular cartilage grafts implanted subdermally into standardized pockets and allocated to four groups: control, nanofat, ADMSCs, and exosomes. The animals were divided into three cohorts according to follow-up duration (4, 12, and 24 weeks; n = 8 per group). Histological evaluation was performed using hematoxylin-eosin, Safranin O/Fast Green, and Toluidine Blue staining to assess morphology and extracellular matrix composition. Collagen type II expression was evaluated by immunohistochemistry and quantified using H-score analysis.
resultsGraft architecture was preserved in all groups without evidence of adverse effects. Nanofat and ADMSC applications demonstrated increased proteoglycan staining compared to controls; however, no significant increase in collagen type II expression was observed. In contrast, exosome treatment resulted in a significant increase in collagen type II expression at 12 weeks (p = 0.035), with sustained improvement observed at 24 weeks.
conclusionADMSC-derived exosomes enhanced cartilage graft viability more effectively than nanofat or ADMSCs. These findings suggest that exosomes may serve as a promising cell-free therapeutic strategy to improve cartilage graft outcomes in reconstructive procedures. NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Indexed as
Identifiers
42722925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.